Epigenomics AG / Veröffentlichung der Gesamtzahl der Stimmrechte
31.10.2013 15:31
Veröffentlichung der Gesamtzahl der Stimmrechte nach § 26a WpHG, übermittelt durch die DGAP - ein Unternehmen der EQS Group AG.
Für den Inhalt der Mitteilung ist der Emittent verantwortlich.
---------------------------------------------------------------------------
Hiermit teilt die Epigenomics AG mit, dass die Gesamtzahl der Stimmrechte
am Ende des Monats Oktober 2013 insgesamt 12118192 Stimmrechte beträgt.
31.10.2013 Die DGAP Distributionsservices umfassen gesetzliche
Meldepflichten, Corporate News/Finanznachrichten und Pressemitteilungen.
DGAP-Medienarchive unter www.dgap-medientreff.de und www.dgap.de
---------------------------------------------------------------------------
Sprache: Deutsch
Unternehmen: Epigenomics AG
Kleine Präsidentenstraße 1
10178 Berlin
Deutschland
Internet: www.epigenomics.com
Ende der Mitteilung DGAP News-Service
---------------------------------------------------------------------------
Archives
31. October 2013
Epigenomics AG: Veröffentlichung der Gesamtzahl der Stimmrechte nach § 26a WpHG mit dem Ziel der europaweiten Verbreitung
29. October 2013
Ad Hoc Announcement Pursuant to §15 WpHG (German Securities Trading Act) Epigenomics AG successfully completes private placement of newly issued shares
Epigenomics AG / Key word(s): Capital Increase
29.10.2013 23:44
Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted
by DGAP - a company of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
Not for distribution in the United States
Berlin, Germany, October 29, 2013 - Today the Executive Board of
Epigenomics AG (Frankfurt Prime Standard: ECX;ISIN: DE000A1K0516) with the
approval of the Supervisory Board has resolved on the increase of the
Company's share capital by EUR 660,260.00 from the authorized capital
2013/I against contribution in cash.The resolution follows a private
placement of 660,260 newly issued shares with institutional investors in
Europe and the U.S.Among others, the owners of Polymedco, Inc.,
Epigenomics' commercialization partner in the U.S., participated in the
transaction.
The issue price has been set at EUR 4.993 per share. This equals the
volume-weighted average Xetra price during the period of the last three
trading days before today's date.The preemptive rights of the shareholders
were excluded. Gross proceeds from this to Epigenomics amounted EUR 3.3 m.
Upon registration of the capital increase with the commercial register
('Handelsregister'), the Company's share capital will increase to EUR
12,996,387.
Epigenomics AG intends to use the net proceeds from this offering to
finance its current operations and to build and strengthen the distribution
capacities for its lead product Epi proColon(R), a blood-based test for the
detection of colorectal cancer.
-End of Ad hoc-
Disclaimer
This publication is not an offer of any securities for sale or a
solicitation of an offer topurchase any securities.
This document is not an offer of securities for sale or a solicitation of
an offer to purchase securities in the United States. The shares of
Epigenomics AG (the 'Shares') have not beenregistered under the U.S.
Securities Act of 1933, as amended (the 'Securities Act') and maynot be
offered or sold in the United States unless registered under the Securities
Act orpursuant to an exemption from such registration. There will be no
public offering of the Sharesin the United States and the Shares will not
be registered under the Securities Act.
Contact:
Epigenomics AG
Antje Zeise CIRO
Manager IR | PR
Epigenomics AG
Phone: +49 (0) 30 24345 386
ir@epigenomics.com
www.epigenomics.com
Epigenomics legal disclaimer
This communication expressly or implicitly contains certain forward-looking
statements concerning Epigenomics AG and its business. Such statements
involve certain known and unknown risks, uncertainties and other factors
which could cause the actual results, financial condition, performance or
achievements of Epigenomics AG to be materially different from any future
results, performance or achievements expressed or implied by such
forward-looking statements. Epigenomics AG is providing this communication
as of this date and does not undertake to update any forward-looking
statements contained herein as a result of new information, future events
or otherwise.
The information contained in this communication does not constitute nor
imply an offer to sell or transfer any product, and no product based on
this technology is currently available for sale by Epigenomics in the
United States or Canada. The analytical and clinical performance
characteristics of any Epigenomics product based on this technology which
may be sold at some future time in the U.S. have not been established.
29.10.2013 DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Epigenomics AG
Kleine Präsidentenstraße 1
10178 Berlin
Germany
Phone: +49 30 24345-0
Fax: +49 30 24345-555
E-mail: ir@epigenomics.com
Internet: www.epigenomics.com
ISIN: DE000A1K0516
WKN: A1K051
Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr
in Berlin, Düsseldorf, München, Stuttgart
End of Announcement DGAP News-Service
---------------------------------------------------------------------------
29. October 2013
Correction Notification: Ad Hoc Announcement Pursuant to §15 WpHG (German Securities Trading Act) Correction of the announcement: Epigenomics AG increases share capital
Epigenomics AG / Key word(s): Capital Increase
29.10.2013 08:55
Dissemination of a Ad-hoc-correction according to § 15 WpHG, transmitted by
DGAP - a company of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
Correction notifaction of the announcement of Epigenomics AG (Frankfurt
Prime Standard: ECX; ISIN: DE000A1K0516) according to § 15 WpHG as of
October 28, 2013 - 9:00 pm CET
Epigenomics erroneously announced yesterday its intention to increase its
share capital by up to EUR 4,136,720.00 from the authorized capital.
Instead, Epigenomics plans to increase its share capital by up to EUR
828,504,00 by issuing new shares at EUR 4.993 per share, thus raising up
to EUR 4,136,720.00 in total gross proceeds. The correct notification is:
Not for distribution in the United States
Berlin,Germany,October 28, 2013- Epigenomics AG (ISIN: DE000A1K0516)
announces that the Company's Executive Board today with the approval of the
Supervisory Board has resolved on an increase of the Company's share
capital by up to EUR 828,504 from the authorized capital,thus raising up to
EUR 4.136.720 in total gross proceeds. This capital increase follows a
previous capital increase, published via ad hoc announcement on October 27,
2013, through which the strategic partner BioChain invested into the
Company. The newly issued shares resulting from the envisagedcapital
increase will be offered against contribution in cashin a private
placementtoinstitutional investors in Europe and the U.S.. The preemptive
rights of the shareholders will be excluded. The issue price has been set
at EUR 4.993 per share andequalsthe volume-weighted average XETRA trading
price duringthe last three trading days including the day of this
announcement.
The placement of the shares is scheduled for Tuesday, October 29, 2013.
Following completion of the placement, the Supervisory and Executive Boards
of the Company are going to resolve on the final amount of shares to be
issued, such resolution to be disclosed by way of an ad hoc announcement
without undue delay.
Epigenomics AG intends to use the net proceeds from the offering to finance
its current operations and to build and strengthen the distribution
capacities for its lead product Epi proColon(R), a blood-based test for the
detection of colorectal cancer.
-End of Ad hoc-
Disclaimer
This publication is not an offer of any securities for sale or a
solicitation of an offer to purchase any securities.
This document is not an offer of securities for sale or a solicitation of
an offer to purchase securities in the United States. The shares of
Epigenomics AG (the 'Shares') have not beenregistered under the U.S.
Securities Act of 1933, as amended (the 'Securities Act') and may not be
offered or sold in the United States unless registered under the Securities
Act or pursuant to an exemption from such registration. There will be no
public offering of the Shares in the United States and the Shares will not
be registered under the Securities Act.
Contact:
Epigenomics AG
Antje Zeise CIRO
Manager IR | PR
Epigenomics AG
Phone: +49 (0) 30 24345 386
ir@epigenomics.com
www.epigenomics.com
Epigenomics legal disclaimer
This communication expressly or implicitly contains certain forward-looking
statements concerning Epigenomics AG and its business. Such statements
involve certain known and unknown risks, uncertainties and other factors
which could cause the actual results, financial condition, performance or
achievements of Epigenomics AG to be materially different from any future
results, performance or achievements expressed or implied by such
forward-looking statements. Epigenomics AG is providing this communication
as of this date and does not undertake to update any forward-looking
statements contained herein as a result of new information, future events
or otherwise.
The information contained in this communication does not constitute nor
imply an offer to sell or transfer any product, and no product based on
this technology is currently available for sale by Epigenomics in the
United States or Canada. The analytical and clinical performance
characteristics of any Epigenomics product based on this technology which
may be sold at some future time in the U.S. have not been established.
29.10.2013 DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Epigenomics AG
Kleine Präsidentenstraße 1
10178 Berlin
Germany
Phone: +49 30 24345-0
Fax: +49 30 24345-555
E-mail: ir@epigenomics.com
Internet: www.epigenomics.com
ISIN: DE000A1K0516
WKN: A1K051
Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr
in Berlin, Düsseldorf, München, Stuttgart
End of Announcement DGAP News-Service
---------------------------------------------------------------------------
28. October 2013
Epigenomics AG: Epigenomics and BioChain enter into broad strategic collaboration in China and investment into Epigenomics
|
Epigenomics AG / Key word(s): Agreement/Capital Increase 28.10.2013 / 08:00
Berlin (Germany) and Newark (California, U.S.A); Beijing (China), October 28, 2013 – Epigenomics AG (Frankfurt Prime Standard: ECX, OTC: EPGNY), the German-American cancer molecular diagnostics company, and BioChain, a leading clinical diagnostics company in cancer and genetic tests in China and the US, today announced that the companies have signed an agreement regarding a broad strategic collaboration of both companies. In addition, BioChain will acquire 217,935 newly issued shares of the company which corresponds to an investment of US$ 1.3m (EUR 0.94m) into Epigenomics. As part of the agreed collaboration, which significantly expands the license agreement for a laboratory developed test announced earlier this year, BioChain will acquire an exclusive license to develop and commercialize Septin9 in vitro diagnostic (IVD) tests for colorectal cancer (CRC) screening in the Chinese market. Under the terms of the agreement, Epigenomics will receive undisclosed upfront and minimum annual payments as well as mid single-digit royalty payments once the product is approved by the CFDA. Until then, Epigenomics will continue selling laboratory developed test (LDT) components to BioChain. At its own expense, BioChain will initiate a major clinical trial to validate the Septin9 CRC screening assay with the goal to gain market approval for the blood-based test by the CFDA. In order to execute the clinical trial, BioChain has placed an order for 5,000 Epi proColon(R) tests with Epigenomics. The trial will start in Q4 2013 and is expected to be completed in the second half of 2014. This is the first clinical study to demonstrate the clinical utility of the Septin9 assay in China, where, in accordance with internationally accepted guidelines, nearly 290 million people are currently eligible for CRC screening. In ChinaCRC is a rapidly growing medical problem demanding for better, simple to use and affordable screening methods. Grace Tian, CEO of BioChain, commented: ‘Based on our assessment of Epigenomics’ test and its significant market potential, we decided to broaden our existing collaboration. We are pleased to introduce this advanced cancer screening test to China and are convinced that the success of this method in the planned clinical trial combined with the simplicity of the Epi proColon(R) test will pave the way to high participation levels in CRC screening in the Chinese population.’ Dr. Thomas Taapken, CEO/CFO of Epigenomics, stated: ‘We are excited about BioChain’s commitment and vigorous approach to accelerate the development of the Chinese CRC screening market with our biomarker. This agreement reached today is the key initial step in translating our blood-based screening assay into a major tool for colorectal cancer management in this important region. We look forward to collaborating closely with our partner BioChain.’ The parties also agreed to work together on the validation of other methylation biomarkers in the cancer field. Epigenomics owns intellectual property around a variety of cancer diagnostic markers for lung, prostate and bladder cancer as well as for other solid tumors and markets a CE-marked product for lung cancer diagnosis based on its proprietary SHOX2 biomarker. BioChain’s advanced sample preparation technology is a valuable asset for the clinical validation of Epigenomics’ other DNA-methylation cancer markers. Should the companies develop any future products, BioChain shall have the option to acquire commercialization rights for the Chinese market, while Epigenomics will retain rights for the rest of the World. – Ends – Contact Epigenomics AG Antje Zeise, Manager IR | PR For US press inquiries: Epigenomics, Inc. About Epigenomics Epigenomics (www.epigenomics.com) is a molecular diagnostics company developing and commercializing a pipeline of proprietary products for cancer. The Company’s products enable doctors to diagnose cancer earlier and more accurately, leading to improved outcomes for patients. Epigenomics’ lead product, Epi proColon(R), is a blood-based test for the early detection of colorectal cancer, which is currently marketed in Europe and is under regulatory review by the FDA for the U.S.A. The Company’s technology and products have been validated through multiple partnerships with leading global diagnostic companies and testing laboratories. Epigenomics is an international company with operations in Europe and the U.S.A. About BioChain BioChain (www.biochain.com, www.biochainbj.com) is a manufacturer of Life Sciences tools and the pioneer of molecular genetics diagnostics in the US and China. It is also the owner and operator of an independent reference laboratory, equivalent of a CLIA lab, in China – Beijing BioChain Medical Laboratory (BBML). BBML is unique in that it focuses on the application of molecular diagnostics technologies and products. BBML is located in the economic development zone of Beijing, China. Through BBML, BioChain is committed to the application of the cutting edge ‘omics’ technologies in the areas of reproductive health and cancer diagnosis. BBML offers comprehensive services to its customers in China with a list of cellular and molecular test menus based on diverse technologies appropriate to each stage and type of disease. Technology platforms employed by BioChain include karyotyping analysis of cytogenetics, fluorescent in-situ hybridization (FISH), array comparative genomic hybridization (aCGH), quantitative PCR (qPCR), Sanger sequencing, next generation sequencing (NGS), multiplex ligation-dependent probe amplification (MLPA), and genetic linkage analysis. BioChain has a strong bioinformatics team and established the first Chromosomal Health Database for the Chinese population (www.szjkzd.org:8080/app/auth). Epigenomics legal disclaimer This communication expressly or implicitly contains certain forward-looking statements concerning Epigenomics AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of Epigenomics AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Epigenomics AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise. The information contained in this communication does not constitute nor imply an offer to sell or transfer any product, and no product based on this technology is currently available for sale by Epigenomics in the United States or Canada. The analytical and clinical performance characteristics of any Epigenomics product based on this technology which may be sold at some future time in the U.S. have not been established. End of Corporate News 28.10.2013 Dissemination of a Corporate News, transmitted by DGAP – a company of EQS Group AG. The issuer is solely responsible for the content of this announcement. DGAP’s Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
| Language: | English | |
| Company: | Epigenomics AG | |
| Kleine Präsidentenstraße 1 | ||
| 10178 Berlin | ||
| Germany | ||
| Phone: | +49 30 24345-0 | |
| Fax: | +49 30 24345-555 | |
| E-mail: | ir@epigenomics.com | |
| Internet: | www.epigenomics.com | |
| ISIN: | DE000A1K0516 | |
| WKN: | A1K051 | |
| Listed: | Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin, Düsseldorf, München, Stuttgart | |
| End of News | DGAP News-Service |
|
|
| 236372 28.10.2013 |
28. October 2013
Ad Hoc Announcement Pursuant to §15 WpHG (German Securities Trading Act): Epigenomics AG increases share capital
Epigenomics AG / Key word(s): Corporate Action
28.10.2013 21:00
Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted
by DGAP - a company of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
Not for distribution in the United States
Berlin, Germany, October 28, 2013 - Epigenomics AG (ISIN: DE000A1K0516)
announces that the Company's Executive Board today with the approval of the
Supervisory Board has resolved on an increase of the Company's share
capital by up to EUR 4,136,720 from the authorized capital. This capital
increase follows a previous capital increase, published via ad hoc
announcement on October 27, 2013, through which the strategic partner
BioChain invested into the Company. The newly issued shares resulting from
the envisaged capital increase will be offered against contribution in cash
in a private placement to institutional investors in Europe and the U.S..
The preemptive rights of the shareholders will be excluded. The issue price
has been set at EUR 4.993 per share and equals the volume-weighted average
XETRA trading price during the last three trading days including the day of
this announcement.
The placement of the shares is scheduled for Tuesday, October 29, 2013.
Following completion of the placement, the Supervisory and Executive Boards
of the Company are going to resolve on the final amount of shares to be
issued, such resolution to be disclosed by way of an ad hoc announcement
without undue delay.
Epigenomics AG intends to use the net proceeds from the offering to finance
its current operations and to build and strengthen the distribution
capacities for its lead product Epi proColon(R), a blood-based test for the
detection of colorectal cancer.
-End of Ad hoc-
Disclaimer
This publication is not an offer of any securities for sale or a
solicitation of an offer to purchase any securities.
This document is not an offer of securities for sale or a solicitation of
an offer to purchase securities in the United States. The shares of
Epigenomics AG (the 'Shares') have not beenregistered under the U.S.
Securities Act of 1933, as amended (the 'Securities Act') and may not be
offered or sold in the United States unless registered under the Securities
Act or pursuant to an exemption from such registration. There will be no
public offering of the Shares in the United States and the Shares will not
be registered under the Securities Act.
Contact:
Epigenomics AG
Antje Zeise CIRO
Manager IR | PR
Epigenomics AG
Phone: +49 (0) 30 24345 386
ir@epigenomics.com
www.epigenomics.com
Epigenomics legal disclaimer
This communication expressly or implicitly contains certain forward-looking
statements concerning Epigenomics AG and its business. Such statements
involve certain known and unknown risks, uncertainties and other factors
which could cause the actual results, financial condition, performance or
achievements of Epigenomics AG to be materially different from any future
results, performance or achievements expressed or implied by such
forward-looking statements. Epigenomics AG is providing this communication
as of this date and does not undertake to update any forward-looking
statements contained herein as a result of new information, future events
or otherwise.
The information contained in this communication does not constitute nor
imply an offer to sell or transfer any product, and no product based on
this technology is currently available for sale by Epigenomics in the
United States or Canada. The analytical and clinical performance
characteristics of any Epigenomics product based on this technology which
may be sold at some future time in the U.S. have not been established.
28.10.2013 DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Epigenomics AG
Kleine Präsidentenstraße 1
10178 Berlin
Germany
Phone: +49 30 24345-0
Fax: +49 30 24345-555
E-mail: ir@epigenomics.com
Internet: www.epigenomics.com
ISIN: DE000A1K0516
WKN: A1K051
Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr
in Berlin, Düsseldorf, München, Stuttgart
End of Announcement DGAP News-Service
---------------------------------------------------------------------------
27. October 2013
Ad hoc Announcement Pursuant to § 15 WpHG (German Securities Trading Act): Epigenomics issues new shares to BioChain – Investment follows agreement on broad strategic collaboration in China
Epigenomics AG / Key word(s): Capital Increase
27.10.2013 19:59
Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted
by DGAP - a company of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
Berlin, Germany, October 27, 2013 - Epigenomics AG (ISIN: DE000A1K0516)
announces that BioChain and certain of its shareholders will invest US$ 1.3
million (EUR 0.94 million) into the Company by subscribing 217,935 newly
issued shares. This investment follows the signing of an agreement
regarding a broad strategic collaboration of both companies announced
today. Executive Board and Supervisory Board of Epigenomics today approved
the increase of the share capital of the company from authorized capital
against contribution in cash. The issue price has been set at EUR 4.32 per
share. This constitutes a 5% discount to the two-day XETRA closing price
average prior to the announcement. After registration of the capital
increase, the subscribed capital of Epigenomics AG will increase from
currently EUR 12,118,192 to EUR 12,336,127.
Epigenomics AG intends to use the net proceeds from the offering to finance
its current operations and to strengthen the distribution capabilities,
especially for its lead product Epi proColon(R), a blood-based test for the
early detection of colorectal cancer.
- End of Ad hoc -
Contact Epigenomics AG
Antje Zeise CIRO
Manager IR | PR
Epigenomics AG
Phone: +49 (0) 30 24345 386
ir@epigenomics.com
www.epigenomics.com
Epigenomics' legal disclaimers. This communication expressly or implicitly
contains certain forward-looking statements concerning Epigenomics AG and
its business. Such statements involve certain known and unknown risks,
uncertainties and other factors which could cause the actual results,
financial condition, performance or achievements of Epigenomics AG to be
materially different from any future results, performance or achievements
expressed or implied by such forward-looking statements. Epigenomics AG is
providing this communication as of this date and does not undertake to
update any forward-looking statements contained herein as a result of new
information, future events or otherwise.
The information contained in this communication does not constitute nor
imply an offer to sell or transfer any product, and no product based on
this technology is currently available for sale by Epigenomics in the
United States or Canada. The analytical and clinical performance
characteristics of any Epigenomicsproduct based on this technology which
may be sold at some future time in the U.S. have not been established.
27.10.2013 DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Epigenomics AG
Kleine Präsidentenstraße 1
10178 Berlin
Germany
Phone: +49 30 24345-0
Fax: +49 30 24345-555
E-mail: ir@epigenomics.com
Internet: www.epigenomics.com
ISIN: DE000A1K0516
WKN: A1K051
Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr
in Berlin, Düsseldorf, München, Stuttgart
End of Announcement DGAP News-Service
---------------------------------------------------------------------------